|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Schiller JH, Harrington D, Belani CP,
Langer C, Sandler A, Krook J, Zhu J and Johnson DH: Eastern
Cooperative Oncology Group: Comparison of four chemotherapy
regimens for advanced non-small-cell lung cancer. N Engl J Med.
346:92–98. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ohe Y, Ohashi Y, Kubota K, Tamura T,
Nakagawa K, Negoro S, Nishiwaki Y, Saijo N, Ariyoshi Y and Fukuoka
M: Randomized phase III study of cisplatin plus irinotecan versus
carboplatin plus paclitaxel, cisplatin plus gemcitabine and
cisplatin plus vinorelbine for advanced non-small-cell lung cancer:
Four-Arm Cooperative Study in Japan. Ann Oncol. 18:317–323. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Fukuoka M, Yano S, Giaccone G, Tamura T,
Nakagawa K, Douillard JY, Nishiwaki Y, Vansteenkiste J, Kudoh S,
Rischin D, et al: Multi-institutional randomized phase II trial of
gefitinib for previously treated patients with advanced
non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin
Oncol. 21:2237–2246. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kris MG, Natale RB, Herbst RS, Lynch TJ
Jr, Prager D, Belani CP, Schiller JH, Kelly K, Spiridonidis H,
Sandler A, et al: Efficacy of gefitinib, an inhibitor of the
epidermal growth factor receptor tyrosine kinase, in symptomatic
patients with non-small cell lung cancer: A randomized trial. JAMA.
290:2149–2158. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kim ES, Hirsh V, Mok T, Socinski MA,
Gervais R, Wu YL, Li LY, Watkins CL, Sellers MV, Lowe ES, et al:
Gefitinib versus docetaxel in previously treated non-small-cell
lung cancer (INTEREST): A randomised phase III trial. Lancet.
372:1809–1818. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Maruyama R, Nishiwaki Y, Tamura T,
Yamamoto N, Tsuboi M, Nakagawa K, Shinkai T, Negoro S, Imamura F,
Eguchi K, et al: Phase III study, V-15-32, of gefitinib versus
docetaxel in previously treated Japanese patients with
non-small-cell lung cancer. J Clin Oncol. 26:4244–4252. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Maemondo M, Inoue A, Kobayashi K, Sugawara
S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I,
et al: Gefitinib or chemotherapy for non-small-cell lung cancer
with mutated EGFR. N Engl J Med. 362:2380–2388. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Mitsudomi T, Morita S, Yatabe Y, Negoro S,
Okamoto I, Tsurutani J, Seto T, Satouchi M, Tada H, Hirashima T, et
al: Gefitinib versus cisplatin plus docetaxel in patients with
non-small-cell lung cancer harbouring mutations of the epidermal
growth factor receptor (WJTOG3405): An open label, randomised phase
3 trial. Lancet Oncol. 11:121–128. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhou C, Wu YL, Chen G, Feng J, Liu XQ,
Wang C, Zhang S, Wang J, Zhou S, Ren S, et al: Erlotinib versus
chemotherapy as first-line treatment for patients with advanced
EGFR mutation-positive non-small-cell lung cancer (OPTIMAL,
CTONG-0802): A multicentre, open-label, randomised, phase 3 study.
Lancet Oncol. 12:735–742. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Rosell R, Carcereny E, Gervais R,
Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R,
Pallares C, Sanchez JM, et al: Erlotinib versus standard
chemotherapy as first-line treatment for European patients with
advanced EGFR mutation-positive non-small-cell lung cancer
(EURTAC): A multicentre, open-label, randomised phase 3 trial.
Lancet Oncol. 13:239–246. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Mok TS, Wu YL, Thongprasert S, Yang CH,
Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, et
al: Gefitinib or carboplatin-paclitaxel in pulmonary
adenocarcinoma. N Engl J Med. 361:947–957. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lin JJ, Cardarella S, Lydon CA, Dahlberg
SE, Jackman DM, Jänne PA and Johnson BE: Five-Year Survival in
EGFR-Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIs.
J Thorac Oncol. 11:556–565. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Noronha V, Joshi A, Gokarn A, Sharma V,
Patil V, Janu A, Purandare N, Chougule A, Jambhekar N and Prabhash
K: The Importance of Brain Metastasis in EGFR Mutation Positive
NSCLC Patients. Chemother Res Pract. 2014:8561562014.PubMed/NCBI
|
|
15
|
Fujimoto D, Ueda H, Shimizu R, Kato R,
Otoshi T, Kawamura T, Tamai K, Shibata Y, Matsumoto T, Nagata K, et
al: Features and prognostic impact of distant metastasis in
patients with stage IV lung adenocarcinoma harboring EGFR
mutations: importance of bone metastasis. Clin Exp Metastasis.
31:543–551. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wu KL, Tsai MJ, Yang CJ, Chang WA, Hung
JY, Yen CJ, Shen CH, Kuo TY, Lee JY, Chou SH, et al: Liver
metastasis predicts poorer prognosis in stage IV lung
adenocarcinoma patients receiving first-line gefitinib. Lung
Cancer. 88:187–194. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wu SG, Yu CJ, Tsai MF, Liao WY, Yang CH,
Jan IS, Yang PC and Shih JY: Survival of lung adenocarcinoma
patients with malignant pleural effusion. Eur Respir J.
41:1409–1418. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Park JH, Kim TM, Keam B, Jeon YK, Lee SH,
Kim DW, Chung DH, Kim YT, Kim YW and Heo DS: Tumor burden is
predictive of survival in patients with non-small-cell lung cancer
and with activating epidermal growth factor receptor mutations who
receive gefitinib. Clin Lung Cancer. 14:383–389. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lee JY, Lim SH, Kim M, Jung HA, Chang WJ,
Choi MK, Hong JY, Lee SJ, Sun JM, Ahn JS, et al: Is there any
predictor for clinical outcome in EGFR mutant NSCLC patients
treated with EGFR TKIs? Cancer Chemother Pharmacol. 73:1063–1070.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Travis WD, Giroux DJ, Chansky K, Crowley
J, Asamura H, Brambilla E, Jett J, Kennedy C, Rami-Porta R, Rusch
VW, et al: The IASLC Lung Cancer Staging Project: proposals for the
inclusion of broncho-pulmonary carcinoid tumors in the forthcoming
(seventh) edition of the TNM Classification for Lung Cancer. J
Thorac Oncol. 3:1213–1223. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kimura H, Fujiwara Y, Sone T, Kunitoh H,
Tamura T, Kasahara K and Nishio K: High sensitivity detection of
epidermal growth factor receptor mutations in the pleural effusion
of non-small cell lung cancer patients. Cancer Sci. 97:642–648.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Mast A and de Arruda M: Invader assay for
single-nucleotide polymorphism genotyping and gene copy number
evaluation. Methods Mol Biol. 335:173–186. 2006.PubMed/NCBI
|
|
24
|
D'Antonio C, Passaro A, Gori B, Del
Signore E, Migliorino MR, Ricciardi S, Fulvi A and de Marinis F:
Bone and brain metastasis in lung cancer: Recent advances in
therapeutic strategies. Ther Adv Med Oncol. 6:101–114. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Weilbaecher KN, Guise TA and McCauley LK:
Cancer to bone: A fatal attraction. Nat Rev Cancer. 11:411–425.
2011. View
Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yoneda T and Hiraga T: Crosstalk between
cancer cells and bone microenvironment in bone metastasis. Biochem
Biophys Res Commun. 328:679–687. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Rahmathulla G, Toms SA and Weil RJ: The
molecular biology of brain metastasis. J Oncol. 2012:7235412012.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Shin DY, Na II, Kim CH, Park S, Baek H and
Yang SH: EGFR mutation and brain metastasis in pulmonary
adenocarcinomas. J Thorac Oncol. 9:195–199. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kim JE, Lee DH, Choi Y, Yoon DH, Kim SW,
Suh C and Lee JS: Epidermal growth factor receptor tyrosine kinase
inhibitors as a first-line therapy for never-smokers with
adenocarcinoma of the lung having asymptomatic synchronous brain
metastasis. Lung Cancer. 65:351–354. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Porta R, Sanchez-Torres JM, Paz-Ares L,
Massutí B, Reguart N, Mayo C, Lianes P, Queralt C, Guillem V,
Salinas P, et al: Brain metastases from lung cancer responding to
erlotinib: The importance of EGFR mutation. Eur Respir J.
37:624–631. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Jamal-Hanjani M and Spicer J: Epidermal
growth factor receptor tyrosine kinase inhibitors in the treatment
of epidermal growth factor receptor-mutant non-small cell lung
cancer metastatic to the brain. Clin Cancer Res. 18:938–944. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Park SJ, Kim HT, Lee DH, Kim KP, Kim SW,
Suh C and Lee JS: Efficacy of epidermal growth factor receptor
tyrosine kinase inhibitors for brain metastasis in non-small cell
lung cancer patients harboring either exon 19 or 21 mutation. Lung
Cancer. 77:556–560. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wu YL, Zhou C, Cheng Y, Lu S, Chen GY,
Huang C, Huang YS, Yan HH, Ren S, Liu Y and Yang JJ: Erlotinib as
second-line treatment in patients with advanced non-small-cell lung
cancer and asymptomatic brain metastases: A phase II study
(CTONG-0803). Ann Oncol. 24:993–999. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Togashi Y, Masago K, Masuda S, Mizuno T,
Fukudo M, Ikemi Y, Sakamori Y, Nagai H, Kim YH, Katsura T and
Mishima M: Cerebrospinal fluid concentration of gefitinib and
erlotinib in patients with non-small cell lung cancer. Cancer
Chemother Pharmacol. 70:399–405. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Lim SH, Lee JY, Sun JM, Ahn JS, Park K and
Ahn MJ: Comparison of clinical outcomes following gefitinib and
erlotinib treatment in non-small-cell lung cancer patients
harboring an epidermal growth factor receptor mutation in either
exon 19 or 21. J Thorac Oncol. 9:506–511. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Goldie JH and Coldman AJ: The genetic
origin of drug resistance in neoplasms: Implications for systemic
therapy. Cancer Res. 44:3643–3653. 1984.PubMed/NCBI
|
|
37
|
Seto T, Kato T, Nishio M, Goto K, Atagi S,
Hosomi Y, Yamamoto N, Hida T, Maemondo M, Nakagawa K, et al:
Erlotinib alone or with bevacizumab as first-line therapy in
patients with advanced non-squamous non-small-cell lung cancer
harbouring EGFR mutations (JO25567): An open-label, randomised,
multicentre, phase 2 study. Lancet Oncol. 15:1236–1244. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Tamiya A, Tamiya M, Shiroyama T, Saijo N,
Nakatani T, Minomo S, Tsuji T, Takeuchi N, Omachi N, Kurata K, et
al: Phase II trial of carboplatin, S-1, and gefitinib as first-line
triplet chemotherapy for advanced non-small cell lung cancer
patients with activating epidermal growth factor receptor
mutations. Med Oncol. 32:402015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Kanda S, Horinouchi H, Fujiwara Y,
Nokihara H, Yamamoto N, Sekine I, Kunitoh H, Kubota K, Tamura T and
Ohe Y: Cytotoxic chemotherapy may overcome the development of
acquired resistance to epidermal growth factor receptor tyrosine
kinase inhibitors (EGFR-TKIs) therapy. Lung Cancer. 89:287–293.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Sugawara S, Oizumi S, Minato K, Harada T,
Inoue A, Fujita Y, Maemondo M, Yoshizawa H, Ito K, Gemma A, et al:
Randomized phase II study of concurrent versus sequential
alternating gefitinib and chemotherapy in previously untreated
non-small cell lung cancer with sensitive EGFR mutations:
NEJ005/TCOG0902. Ann Oncol. 26:888–894. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Park K, Tan EH, O'Byrne K, et al: Afatinib
versus gefitinib as first-line treatment of patients with EGFR
mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase
2B, open-label, randomised controlled trial. Lancet Oncol.
17:577–589. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Dempke WC, Edvardsen K, Lu S, Reinmuth N,
Reck M and Inoue A: Brain Metastases in NSCLC-are TKIs changing the
treatment strategy? Anticancer Res. 35:5797–5806. 2015.PubMed/NCBI
|
